Tag

2 results found for: prescribing review

What's the cost of NHS savings?

NHS England’s review of “low value” prescription items has the potential to save up to £400 million a year, but what could be the implications?

Reasons to welcome the prescribing review

What’s been happening under cover with prescribing is now out in the open, says Noel Wicks It seems that NHS England is taking a leaf out of the book of certain CCGs with its recent announcement to review a selection of “low value” medicines that it believes may have limited clinical value. The 10 items include tadalafil, travel vaccines, lidocaine plasters, fentanyl and doxazosin. In total, this could yield about £130 million in savings, although I imagine this assumes that no alternatives are prescribed. This seems a far cry from the £400 million that Simon Stevens suggested could be saved by this review. So where is the rest coming from? Alongside this initial list of specified medicines NHS England also intends review other areas such as gluten-free foods and minor ailments including hayfever, pain and indigestion.

Latest News

Pharmacy Winter action – take to social media today!

Pharmacy teams are being asked to join in with today's #pharmacywinter action day

Call to extend NHS health checks

The NPA has responded to a report by think tank ResPublica which calls for community pharmacy to provide health checks...

Views

OTC prescribing: where local policy is taking the lead

Dudley CCG’s decision on self care medicines is an interesting approach, says Noel Wicks It seems that the saga surro...

Popular Features

Promoting back to school health

The start of a new term is an opportunity for community pharmacy to put children’s health centre stage

Look differently at the supervision debate

There are other priorities to be tackled before any proposed changes to supervision, suggests Noel Wicks Supervision se...

Avicenna pharmacies show growth in company’s 25th year

Avicenna pharmacies have increased their number of prescription items by two per cent across the company against a natio...